Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-16
2011-08-16
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S398000, C548S343500, C548S311100, C548S316400, C548S321500
Reexamination Certificate
active
07998995
ABSTRACT:
Compounds of the invention are disclosed, such as compounds of formulae LX-LXIV, and pharmaceutically acceptable salts, isomers, or prodrugs thereof, which are useful as modulators of the activity of liver X receptors (LXR) and Farnesoid X receptors (FXR), where R00, R200, R400, R500, J11, J21, G1, G21, and Q are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
REFERENCES:
patent: 5466823 (1995-11-01), Talley et al.
patent: 5504215 (1996-04-01), Talley et al.
patent: 5760068 (1998-06-01), Talley et al.
patent: 6071955 (2000-06-01), Elias et al.
patent: 6184215 (2001-02-01), Elias et al.
patent: 6294558 (2001-09-01), Ando et al.
patent: 6358634 (2002-03-01), Igarashi et al.
patent: RE37936 (2002-12-01), Huang et al.
patent: 6492411 (2002-12-01), Talley et al.
patent: 6635655 (2003-10-01), Jayyosi et al.
patent: 7566709 (2009-07-01), Schiemann et al.
patent: 2002/0035156 (2002-03-01), Roniker et al.
patent: 2004/0152739 (2004-08-01), Hanau et al.
patent: 2004/0157883 (2004-08-01), Chen et al.
patent: 2004/0248956 (2004-12-01), Hagmann et al.
patent: 2005/0004115 (2005-01-01), Sharma et al.
patent: 2006/0241157 (2006-10-01), Conner et al.
patent: 2006/0276650 (2006-12-01), Schadt et al.
patent: 2007/0010531 (2007-01-01), Schadt et al.
patent: 2008/0090834 (2008-04-01), Hoover et al.
patent: 103 15 569 (2004-10-01), None
patent: 103 15 571 (2004-10-01), None
patent: 103 15 573 (2004-10-01), None
patent: 0 839 810 (1998-05-01), None
patent: 1 285 908 (2003-02-01), None
patent: 1 398 029 (2004-03-01), None
patent: 1 884 513 (2008-02-01), None
patent: 2004-146368 (2004-05-01), None
patent: 03/086287 (2003-10-01), None
patent: 2004/011446 (2004-02-01), None
patent: 2004/033432 (2004-04-01), None
patent: 2004/056740 (2004-07-01), None
patent: 2004/069158 (2004-08-01), None
patent: 2004/071447 (2004-08-01), None
patent: 2004/080972 (2004-09-01), None
patent: 2004/089303 (2004-10-01), None
patent: 2004/089888 (2004-10-01), None
patent: 2004/089932 (2004-10-01), None
patent: 2004/106307 (2004-12-01), None
patent: 2005/009435 (2005-02-01), None
patent: 2005/012263 (2005-02-01), None
patent: 2005/037199 (2005-04-01), None
patent: 2005/037763 (2005-04-01), None
patent: 2005037271 (2005-04-01), None
patent: 2005/044130 (2005-05-01), None
patent: 2005/047266 (2005-05-01), None
patent: 2005/049578 (2005-06-01), None
patent: 2005/054176 (2005-06-01), None
patent: 2005/066137 (2005-07-01), None
patent: 2006/044528 (2006-04-01), None
patent: 2006/076202 (2006-07-01), None
patent: 2007/002559 (2007-01-01), None
patent: 2007/002559 (2007-01-01), None
patent: 2007/002563 (2007-01-01), None
U.S. Appl. No. 2009-993529, concurrently owned, filed Dec. 4, 2009.
Finn et al., “Discovery of a potent and selective series of pyrazole bacterial methionyl-trna sythetase inhibitors” Bioorganic & Medicinal Chemistry Letters, 13(13), 2003, 2231-2234.
Bennett et al.,“Liver X receptor agonist as a treatment for atherosclerosis”, Expert Opinion on Therapeutic Patents, 2004, 14(7), 967-982.
Tischenko et al., “Some derivatives of 1,2,5-triphenylimidazole”, Deposited Doc. (1980) SPSTL 358Khp-D80, Caplus Accession No. 1982:423694, 8pp.
Tischenko et al., “Synthesis and luminescence of 1,2,5-triphenylimidazoles”, Sisintill Org Lyuminofory, 1972, 93-9.
Lettau et al., “Imidazol-N-oxide 1); Eline einfache Synthese substituierter Imidazole”, Zeischrift fuer Chemie, 1971, 11(1), 10-11.
Weissenfels et al., “Diimidazoles. II. Synthesis of aliphatically and aromatically bridged N,N'-diimidazoles”, Journal fuer Praktische Chemie (Leipzig), 1963, 22(3-4), 130-9.
Yanborisov et al., “Synthesis and pharmaceutical activity of heteroylpyruvic acids and their derivatives”, Khimiko-Farmatsevticheskii Zhurnal [Pharmaceutical Chemistry Journal], 1998, 32(9), 480-2.
Kalaany et al., “LXRs regulate the balance between fat storage and oxidation”, Cell Metabolism, 2005, vol. 1, 231-244 and Supplemental Data (4 sheets).
Giorelli et al., “Immunomodulatory properties of increased levels of liver X receptor β in peripheral blood mononuclear cells from multiple sclerosis patients”, Experimental Neurology, 2007, vol. 204, 759-766.
Zanlungo et al., “The Molecular and Metabolic Basis of Biliary Cholesterol Secretion and Gallstone Disease”, Frontiers in Bioscience, 2003, vol. 8, 1166-1174.
Zelcer et al., “Liver X receptors as integrators of metabolic and inflammatory signaling”, The Journal of Clinical Investigation, 2006, 116(3), 607-614.
Joseph et al., “Synthetic LXR ligand inhibits the development of atherosclerosis in mice”, PNAS, 2002, 99(11), 7604-7609.
Tontonoz et al., “Liver X Receptor Signaling Pathways in Cardiovascular Disease”, Molecular Endocrinology, 2003, 17(6), 985-993.
Goralski et al., “Chipping away at gallstones”, Nature Medicine, 2004, 10(12), 1301-1302.
Boren Brant Clayton
Busch Brett B.
Gu Xiao-Hui
Jammalamadaka Vasu
Lu Shao Po
Barker Michael
Chu Yong
Exelixis Patent Company LLC
Fox Rothschild LLP
Norton Gerard P.
LandOfFree
LXR and FXR modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with LXR and FXR modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and LXR and FXR modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2719434